ALDH3A1 inhibitor EN40

Research use only, not for human use.

ALDH3A1 inhibitor EN40 is a potent and selective, covalent, in vivo-active inhibitor of ALDH3A1 with IC50 of 2 uM.

ALDH3A1 inhibitor EN40 is a potent and selective, covalent, in vivo-active inhibitor of ALDH3A1 with IC50 of 2 uM, demonstrates no activity against ALDH1A3 and ALDH6A1 at 30 uM; also does not show any observable competition against lysine-reactive probe labeling of A549 proteomes; specifically inhibits the lung cancer cell lines expressing ALDH3A1, but not in the cell lines that do not express ALDH3A1, inhibits ALDH3A1 activity and impairs lung cancer pathogenicity in vivo.

Cell Viability Assay Cell Line:A549 cells Concentration:10 μM; 100 μM; 1000 μM Incubation Time:48 hours Result:Inhibited A549 cells survival.

Animal Model:SCID mice with A549 cellsDosage:50 mg/kg Administration:Intraperitoneal injection; 50mg/kg; from 14 days; once per day Result:Had strong anti-tumorigenic effects in tumor xenografts.

EN-40 | EN 40 | EN40

Metabolic Enzyme/Protease

ALDH

ALDH

——

——

2094547-67-6

217.268

C13H15NO2

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (460.28 mM)

C=CC(N1CC(C2=CC=CO2)=C(C)CC1)=O

1-(5-(furan-2-yl)-4-methyl-3,6-dihydropyridin-1(2H)-yl)prop-2-en-1-one

(-20℃)

With Ice Pack

≥ 2 years